Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Mihran H. Shirinian

Hematology Oncology | Oncology | Hematology
1505 Wilson Ter, Suite 340, 
Glendale, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
1505 Wilson Ter, Suite 340, 
Glendale, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mihran Shirinian is a Hematologist Oncology specialist and an Oncologist in Glendale, California. Dr. Shirinian is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Acute Erythroid Leukemia (AEL), Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Keck Hospital Of USC
Glendale Adventist Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

1505 Wilson Ter, Suite 340, Glendale, CA 91206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Journal: International journal of colorectal disease
Published: December 24, 2023
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Ronald L. Paquette
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Ronald L. Paquette
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (10.0 miles away)
310-423-3277
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ronald Paquette is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Paquette is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Myelofibrosis, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. David Snyder
Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. David Snyder
Hematology | Oncology
1500 E Duarte Rd, 
Duarte, CA 
 (14.8 miles away)
626-359-8111
Languages Spoken:
English

David Snyder is a Hematologist and an Oncologist in Duarte, California. Dr. Snyder is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Colonoscopy.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (6.2 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell is rated as an Elite provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Polycythemia Vera, Myelofibrosis, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shirinian's expertise for a condition
ConditionClose
    View All 30 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile